NOVÁ DOPORUČENÍ / NEW RECOMMENDATIONS Angiotensin II – mechanismus účinku, současná evidence a stanovisko mezioborové pracovní skupiny k jeho použití na pracovištích intenzivní péče | 51 / Anest intenziv Med. 2025;36(1):46-51 / ANESTEZIOLOGIE A INTENZIVNÍ MEDICÍNA www.aimjournal.cz 13. Chappell MC, Schaich CL, Busse LW, Martin GS, Sevransky JE, Hinson JK, et al. Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post‑hoc analysis from the VICTAS trial. Crit Care. 2024;28(1):333. 14. Eleuteri D, Montini L, Cutuli SL, Rossi C, Alcaro F, Antonelli M. Renin‑angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: a preliminary report. Crit Care. 2021;25(1):91. 15. Heinicke U, Adam E, Sonntagbauer M, von Knethen A, Zacharowski K, Neb H. Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single‑center experience. Crit Care. 2020;24(1):409. 16. Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med. 2017;45(8):1285-94. 17. Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, et al. NOREPINEPHRINE: NOT TOO MUCH, TOO LONG. Shock. 2015;44(4):305-9. 18. Legrand M, Khanna AK, Ostermann M, Kotani Y, Ferrer R, Girardis M, et al. The renin ‑angiotensin‑aldosterone‑system in sepsis and its clinical modulation with exogenous angiotensin II. Crit Care. 2024;28(1):389. 19. Ostermann M, Boldt DW, Harper MD, Lim GW, Gunnerson K. Angiotensin in ECMO patients with refractory shock. Crit Care. 2018;22(1):288. 20. Levy B, Lescroart M, Combes A. Use of vasopressors and inotropes in ECMO. Intensive Care Med. 2024;50(3):463-6. 21. Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery ‑review of pathophysiology and update of treatment options. Crit Care. 2020;24(1):36. 22. Bansal M, Mehta A, Wieruszewski PM, Belford PM, Zhao DX, Khanna AK, et al. Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review. Am J Emerg Med. 2023;66:124-8. 23. Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK. Angiotensin II for Critically Ill Patients With Shock After Heart Transplant. J Cardiothorac Vasc Anesth. 2021;35(9):275662. 24. Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED. Synthetic Human Angiotensin II for Postcardiopulmonary Bypass Vasoplegic Shock. J Cardiothorac Vasc Anesth. 2019;33(11):3080-4. 25. Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. Lancet. 1993;341(8846):703. 26. Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol. 1995;40(1):103-4. 27. Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother. 1994;28(10):1165-8. 28. Chen A, Wong A. The Role of Angiotensin II in Poisoning‑Induced Shock‑a Review. J Med Toxicol. 2022;18(2):145-54. 29. Lambden S, Creagh‑Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Crit Care. 2018;22(1):174. 30. Ratnani I, Ochani RK, Shaikh A, Jatoi HN. Vasoplegia: A Review. Methodist Debakey Cardiovasc J. 2023;19(4):38-47. 31. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-87. 32. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. Jama. 2016;316(5):509-18. 33. Balik M, Novotny A, Suk D, Matousek V, Maly M, Brozek T, et al. Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction. Cardiovasc Drugs Ther. 2020;34(5):685-8. 34. Chawla LS, Busse L, Brasha‑Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high‑output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534. 35. Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R. Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Crit Care. 2020;24(1):227. 36. Agency EM. EU Panel Backs Angiotensin II (Giapreza) for Septic Shock 28. 6. 2019 37. Caragata R, Johnston SA, Chan JW, Starkey G, Bellomo R. Angiotensin‑II and Thromboembolic Events: A Systematic Review. Crit Care Med. 2024;52(12):1894-905. 38. Legrand M, Zarbock A. Ten tips to optimize vasopressors use in the critically ill patient with hypotension. Intensive Care Med. 2022;48(6):736-9.
RkJQdWJsaXNoZXIy NDA4Mjc=